Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

January 2016 in “ Journal of clinical biochemistry and nutrition ”

Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Koichi Uchida, Koichi Fujisawa, Toshihiko Matsumoto, Issei Saeki, Shuji Terai, Isao Sakaida

deferasirox iron chelator sorafenib hand-foot skin syndrome hepatocellular carcinoma liver fibrosis preneoplastic lesions DFX HCC

TLDR Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

The study demonstrated that deferasirox (DFX), an oral iron chelator, effectively reduced liver fibrosis and hepatocarcinogenesis in a rat model, particularly when combined with sorafenib. This combination therapy significantly decreased preneoplastic lesions and adverse effects like hand-foot skin syndrome, commonly associated with sorafenib. The findings suggested that DFX could be a promising adjunct therapy to enhance the efficacy and reduce the side effects of sorafenib in treating hepatocellular carcinoma (HCC).

View this study on jstage.jst.go.jp →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Pathogenesis of Hand-Foot Syndrome Induced by PEG-Modified Liposomal Doxorubicin

63 citations, February 2013 in “Human cell”

PEGL-DOX causes Hand-Foot Syndrome due to skin reactions from prolonged circulation and ROS generation.

Similar Research

5 / 7 results

research Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox

April 2023 in “Tikrit Journal of Pharmaceutical Sciences”

The study on 85 patients with ß-thalassemia in Kirkuk, Iraq, found that deferasirox, an oral iron chelator, effectively reduced serum ferritin levels in 55.3% of patients, indicating a decrease in iron overload. Some adverse effects were observed, including elevated serum creatinine in 25.8% of patients, elevated liver enzymes, and hair loss in 2 patients. Despite these side effects, deferasirox was generally well-tolerated, and its adverse effects could be managed by adjusting the dosage. The study concludes that deferasirox is a suitable treatment for managing iron overload in ß-thalassemia patients.

research Section 2: Single Best Answer Questions 51–120

January 2016

The document tests knowledge and decision-making in hematology through multiple-choice questions.

Single Best Answers for Hematology Specialist Trainees

Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

Research cited in this study

research Pathogenesis of Hand-Foot Syndrome Induced by PEG-Modified Liposomal Doxorubicin

Related Community Posts Join

Similar Research

research Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox

research Section 2: Single Best Answer Questions 51–120

research Single Best Answers for Hematology Specialist Trainees

research Advancements and Applications of Injectable Hydrogel Composites in Biomedical Research and Therapy

research Antiviral Drugs Prolong Survival in Murine Recessive Dystrophic Epidermolysis Bullosa